JAMA Psychic: Adolescent depressed patients who receive 5-serotonin reuptake inhibitors have an increased risk of diabetes in adults.

Researchers recently examined the relationship between selective 5-serotonin reuptake inhibitors (SSRIs) in children and adolescents and the risk of type 2 diabetes (T2D) in adults.
2000-15, children aged 10-19 who were treated with SSRI participated in the study, which was analyzed in 2018-19, with the main endpoint of the study being diabetes events.
1582,914 participants, 58.3 per cent of whom were women, with an average age of 15.1 years.
SSRI treatment group included 316,178 patients in the MAX Public Health Insurance Database (average age 14.7 years, 62.2% female) and 211,460 patients in the MarketScan Commercial Insurance Database (average age 15.8 years; 63.9% female).
In publicly insured patients, starting SSRI treatment increased the risk of T2DM by 13% compared to those who did not receive SSRI treatment, and the correlation caused by ongoing SSRI treatment continued to increase, equivalent to 6.6 additional cases of T2D for every 10,000 patients treated for at least 2 years.
in privately insured patients, the correlation between SSRI therapy and T2DM risk was reduced after adjustment (1.01).
the risk of T2DM (1.44) was increased compared to psychotherapy, while the risk of T2D was not significantly increased compared to the representative drug fluoxetine and acetatin.
study found that patients with depression in children and adolescents who received selective 5-serotonin reuptake inhibitors led to a slight increased risk of type 2 diabetes in adults.
.